Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cgh.2021.04.039 http://scihub22266oqcxt.onion/10.1016/j.cgh.2021.04.039 33940227!ä!33940227 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Gastroenterol+Hepatol 2021 ; 19 (9): 1970-1972.e3 Nephropedia Template TP {{tp|p=33940227|t=2021. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study |pdf=|usr=}}{{33940227}} gab.com Text Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study JO: Clin Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=33940227 #FOAvip Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)(1-4) and was first approved for COVID-19 patients.(5) However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.(1-4)(,)(6) Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports. Twit Text FOAVip Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study ????Clin Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=33940227 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33940227 #FOAvip English Wikipedia <ref>{{Cite pmid|33940227}}</ref> Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study #MMPMID33940227 Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L Clin Gastroenterol Hepatol 2021[Sep]; 19 (9): 1970-1972.e3 PMID33940227show ga Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)(1-4) and was first approved for COVID-19 patients.(5) However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.(1-4)(,)(6) Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports. |*COVID-19 Drug Treatment[MESH] |*Drug-Related Side Effects and Adverse Reactions/epidemiology[MESH] |Adenosine Monophosphate/analogs & derivatives[MESH] |Adverse Drug Reaction Reporting Systems[MESH] |Alanine/analogs & derivatives[MESH] |Databases, Factual[MESH] |Humans[MESH] |Pharmacovigilance[MESH] |SARS-CoV-2[MESH]Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The W(epmc).pdf DeepDyve Pubget Overpricing